| ROI Name | ∑ In | % In | log ratio | ∑ Out | % Out |
|---|---|---|---|---|---|
| AL(R) | 324 | 100.0% | 0.57 | 482 | 99.8% |
| CentralBrain-unspecified | 0 | 0.0% | inf | 1 | 0.2% |
| LAL(R) | 0 | 0.0% | 0.00 | 0 | 0.0% |
| upstream partner | # | NT | conns TRN_VP3b | % In | CV |
|---|---|---|---|---|---|
| lLN2F_a (R) | 2 | unc | 74 | 26.6% | 0.1 |
| lLN2F_b (R) | 2 | GABA | 52 | 18.7% | 0.1 |
| TRN_VP3a | 3 | ACh | 33 | 11.9% | 0.4 |
| lLN2X04 (R) | 2 | ACh | 16 | 5.8% | 0.2 |
| lLN2R_a (R) | 2 | GABA | 12 | 4.3% | 0.3 |
| HRN_VP1l | 4 | ACh | 11 | 4.0% | 0.9 |
| CB1048 (R) | 1 | Glu | 10 | 3.6% | 0.0 |
| l2LN22 (R) | 2 | unc | 10 | 3.6% | 0.0 |
| lLN2X11 (R) | 2 | ACh | 8 | 2.9% | 0.0 |
| lLN2T_a (R) | 2 | ACh | 7 | 2.5% | 0.4 |
| lLN1_bc (R) | 5 | ACh | 7 | 2.5% | 0.3 |
| lLN2T_b (R) | 2 | ACh | 6 | 2.2% | 0.3 |
| l2LN20 (R) | 2 | GABA | 5 | 1.8% | 0.2 |
| lLN2X05 (R) | 1 | ACh | 4 | 1.4% | 0.0 |
| lLN2P_c (R) | 2 | GABA | 4 | 1.4% | 0.0 |
| ALIN5 (L) | 1 | GABA | 3 | 1.1% | 0.0 |
| VP3+VP1l_ivPN (L) | 1 | ACh | 3 | 1.1% | 0.0 |
| lLN2P_b (R) | 1 | GABA | 2 | 0.7% | 0.0 |
| lLN2T_e (R) | 1 | ACh | 2 | 0.7% | 0.0 |
| M_smPN6t2 (L) | 1 | GABA | 2 | 0.7% | 0.0 |
| lLN2T_c (R) | 1 | ACh | 2 | 0.7% | 0.0 |
| lLN2X12 (R) | 1 | ACh | 1 | 0.4% | 0.0 |
| v2LN49 (R) | 1 | Glu | 1 | 0.4% | 0.0 |
| VP3+VP1l_ivPN (R) | 1 | ACh | 1 | 0.4% | 0.0 |
| DNb02 (R) | 1 | Glu | 1 | 0.4% | 0.0 |
| OA-VUMa5 (M) | 1 | OA | 1 | 0.4% | 0.0 |
| downstream partner | # | NT | conns TRN_VP3b | % Out | CV |
|---|---|---|---|---|---|
| VP3+_vPN (R) | 1 | GABA | 299 | 21.3% | 0.0 |
| lLN2F_a (R) | 2 | unc | 164 | 11.7% | 0.0 |
| VP3+VP1l_ivPN (L) | 1 | ACh | 116 | 8.3% | 0.0 |
| v2LN49 (R) | 2 | Glu | 105 | 7.5% | 0.3 |
| VP3+VP1l_ivPN (R) | 1 | ACh | 99 | 7.1% | 0.0 |
| CB1048 (R) | 3 | Glu | 68 | 4.9% | 0.7 |
| lLN2X11 (R) | 2 | ACh | 53 | 3.8% | 0.0 |
| lLN2T_a (R) | 2 | ACh | 47 | 3.4% | 0.5 |
| lLN2X04 (R) | 2 | ACh | 43 | 3.1% | 0.6 |
| VP3+_l2PN (R) | 3 | ACh | 42 | 3.0% | 0.8 |
| VP1l+VP3_ilPN (R) | 1 | ACh | 41 | 2.9% | 0.0 |
| l2LN20 (R) | 2 | GABA | 34 | 2.4% | 0.2 |
| lLN2X12 (R) | 5 | ACh | 32 | 2.3% | 0.4 |
| VP1l+VP3_ilPN (L) | 1 | ACh | 31 | 2.2% | 0.0 |
| TRN_VP3a | 3 | ACh | 31 | 2.2% | 0.2 |
| lLN2F_b (R) | 2 | GABA | 30 | 2.1% | 0.2 |
| l2LN22 (R) | 2 | unc | 17 | 1.2% | 0.6 |
| lLN2R_a (R) | 2 | GABA | 17 | 1.2% | 0.6 |
| M_l2PNm16 (R) | 2 | ACh | 11 | 0.8% | 0.1 |
| lLN2T_b (R) | 2 | ACh | 10 | 0.7% | 0.6 |
| VP1l+_lvPN (R) | 2 | ACh | 10 | 0.7% | 0.4 |
| v2LN4 (R) | 2 | ACh | 10 | 0.7% | 0.2 |
| HRN_VP1l | 3 | ACh | 10 | 0.7% | 0.5 |
| lLN1_bc (R) | 6 | ACh | 9 | 0.6% | 0.5 |
| M_imPNl92 (R) | 1 | ACh | 7 | 0.5% | 0.0 |
| lLN2P_c (R) | 2 | GABA | 7 | 0.5% | 0.7 |
| M_ilPNm90 (L) | 1 | ACh | 6 | 0.4% | 0.0 |
| VP1m+_lvPN (R) | 2 | Glu | 6 | 0.4% | 0.7 |
| M_smPN6t2 (L) | 1 | GABA | 5 | 0.4% | 0.0 |
| lLN2X05 (R) | 2 | ACh | 5 | 0.4% | 0.6 |
| VP4_vPN (R) | 1 | GABA | 4 | 0.3% | 0.0 |
| CSD (L) | 1 | 5-HT | 4 | 0.3% | 0.0 |
| OA-VUMa2 (M) | 1 | OA | 4 | 0.3% | 0.0 |
| CB4083 (R) | 1 | Glu | 3 | 0.2% | 0.0 |
| lLN2P_b (R) | 2 | GABA | 3 | 0.2% | 0.3 |
| M_ilPNm90 (R) | 1 | ACh | 2 | 0.1% | 0.0 |
| DNb02 (R) | 1 | Glu | 2 | 0.1% | 0.0 |
| VP3+_l2PN (L) | 1 | ACh | 2 | 0.1% | 0.0 |
| CSD (R) | 1 | 5-HT | 2 | 0.1% | 0.0 |
| lLN2T_e (R) | 2 | ACh | 2 | 0.1% | 0.0 |
| ALIN5 (L) | 1 | GABA | 1 | 0.1% | 0.0 |
| v2LN50 (R) | 1 | Glu | 1 | 0.1% | 0.0 |
| LHAD4a1 (R) | 1 | Glu | 1 | 0.1% | 0.0 |
| VP5+VP3_l2PN (R) | 1 | ACh | 1 | 0.1% | 0.0 |
| M_l2PN3t18 (R) | 1 | ACh | 1 | 0.1% | 0.0 |
| WED069 (R) | 1 | ACh | 1 | 0.1% | 0.0 |
| M_imPNl92 (L) | 1 | ACh | 1 | 0.1% | 0.0 |
| lLN2T_c (R) | 1 | ACh | 1 | 0.1% | 0.0 |
